BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) COVID-19 NanoAb Takes Centerstage at the 2023 BIO CEO & Investor Conference
Amir Reichman, BiondVax CEO, represented the company at this year’s BIO CEO & Investor Conference held at the Marriott Marquis, New York, on February 6-8 His presentation focused on the company’s recent successful pre-clinical in vivo results on its innovative inhaled COVID-19 treatment Additional results from the study were release in January 2023, indicating that, compared to the control group, hamsters that received the drug one day after infection had negligible SARS-CoV-2 vital titers in their lungs and experienced a significantly milder and shorter illness BiondVax’s management is optimistic that its self-administered inhaled NanoAbs will be highly attractive to at-risk…